New Study Published in JAMA Oncology Shows MammaPrint Changed Breast Cancer Treatment Decisions in 3 out of 4 Cases where Guidance was Unclear with the 21-Gene Assay

October 26, 2017

Prospective PROMIS trial showed no correlation between the two tests highlighting potential under-and over-treatment risks throughout the 21-gene assay’s intermediate range Physicians changed their treatment decisions in approximately 34% of all cases and in 76% of cases where treatment decisions were discordant based on the indication of the MammaPrint test, with 79% of physicians having…

Read more

Breast Cancer is the Most Feared Cancer Among Women in Germany, Although Less than Half are Aware of the Benefits of Genomic Testing

October 9, 2017

KANTAR survey: Only 40% of breast cancer patients know the benefits of genomic testing IRVINE, CA and AMSTERDAM, 9 October 2017 –  Breast cancer is the most feared type of cancer among women in Germany, according to a recent representative survey commissioned by Agendia, a world leader in personalized medicine and molecular cancer diagnostics. 21%…

Read more

Breast Cancer – Let’s Make It Personal: Agendia Supports Breast Cancer Awareness Month with International Program of Activities

September 27, 2017

Flash Mob for Breast Cancer Empowerment, in partnership with the Tigerlily Foundation, takes place at the Lincoln Memorial in Washington, DC on Saturday 14 October International events including support of Susan G. Komen Race for the Cure in Orange County, ‘Boxing Against Breast Cancer’ in Amsterdam and a Dress in Pink Day New patient stories,…

Read more

10-Year Prospective Outcome Data and MINDACT Sub-Study Presented at ESMO Congress Demonstrate Prognostic Value of MammaPrint in Personalizing Early-Stage Breast Cancer Treatment

September 13, 2017

First time 10-year prospective outcome data confirms clinical utility of MammaPrint for lymph node-negative and lymph node-positive patients MINDACT sub-study shows that even tumors less than 1cm in size can be aggressive with 24% reclassified by MammaPrint from low risk based on clinico-pathological factors to High Risk   IRVINE, CA and AMSTERDAM – 13 September…

Read more